Form 4: Sutro Biopharma CFO Gregory Chow Receives Significant Equity Awards

Sutro Biopharma, Inc. (STRO) has granted its Chief Financial Officer, Gregory K. Chow, new equity compensation in the form of stock options and restricted stock units, aligning his long-term incentives with shareholder value.

Summary

• Gregory K. Chow, the Chief Financial Officer of Sutro Biopharma, Inc. (STRO), was granted new equity awards on June 2, 2025.
• The awards include 275,000 stock options with an exercise price of $0.9 per share, expiring on June 2, 2035.
• The stock options vest 25% on June 2, 2026, with the remainder vesting ratably at 1/48th of the total award monthly thereafter, contingent on continued service.
• Additionally, Mr. Chow received 100,000 Restricted Stock Units (RSUs), each representing a contingent right to receive one share of Common Stock, expiring on June 2, 2029.
• The RSU award vests annually as to 1/4th of the total award beginning on June 2, 2026, also subject to continued service to the Issuer.

Sentiment

Score: 7

Explanation: The sentiment is positive as it reflects a standard and beneficial practice of aligning executive incentives with shareholder interests through long-term equity awards. It indicates stability in key management and a commitment to future performance.

Positives

• The grant of significant equity awards to the CFO aligns his financial interests directly with the long-term performance and shareholder value of Sutro Biopharma.
• Equity compensation is a standard and effective way to incentivize key executives to remain with the company and contribute to its growth.
• The long vesting schedules for both options (4 years) and RSUs (4 years) indicate a commitment to retaining key management over an extended period.

Risks

• The vesting of both the stock options and Restricted Stock Units is subject to the reporting person's continued service to the Issuer on each vesting date, meaning the awards could be forfeited if employment ceases.

Future Outlook

The equity awards are designed to incentivize the CFO's long-term commitment and performance, with vesting schedules extending through June 2029 for RSUs and June 2035 for stock options, indicating a strategic focus on sustained executive alignment with future company growth.

Industry Context

The granting of stock options and restricted stock units to key executives like the CFO is a common practice in the biotechnology and pharmaceutical industry. This form of compensation is widely used to attract, retain, and motivate top talent, aligning their long-term financial interests with the company's success and shareholder returns, particularly in a sector characterized by long development cycles and significant R&D investment.

Comparison to Industry Standards

• The structure of these equity awards, including a mix of stock options and RSUs with multi-year vesting schedules, is consistent with typical executive compensation packages observed across the biotechnology and pharmaceutical industry.
• While specific award sizes vary by company size, stage, and individual role, the use of performance-based or time-based vesting tied to continued service is a standard mechanism to ensure executive retention and alignment with long-term corporate objectives, similar to practices at comparable biotech firms like Moderna, BioNTech, or Regeneron Pharmaceuticals.

Corporate Governance

Related Party Transactions

• The transaction involves the grant of equity awards by Sutro Biopharma, Inc. to its Chief Financial Officer, Gregory K. Chow, which constitutes a related party transaction as it is between the company and a key management personnel.

Stakeholder Impact

• Shareholders: The equity awards align the CFO's financial interests with shareholder value, potentially leading to better long-term performance and increased share price.
• Employees: While specific to the CFO, such compensation practices can signal a stable and incentivized leadership team, which can positively impact overall employee morale and retention.
• Management: The awards provide significant long-term incentives for the CFO, encouraging continued service and dedication to the company's strategic goals.

Next Steps

• The stock options will begin vesting on June 2, 2026, with 25% of the award, and continue monthly thereafter.
• The Restricted Stock Units (RSUs) will begin annual vesting on June 2, 2026, with 1/4th of the total award.

Key Dates

Keywords

Sutro Biopharma, STRO, Form 4, Insider Transaction, Equity Compensation, Stock Options, Restricted Stock Units, CFO, Executive Compensation, Beneficial Ownership